Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-01-31 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about a change in the company's website address. It is dated January 31, 2024, and is addressed to BSE Limited and National Stock Exchange of India Ltd. The content is purely informational and does not contain any financial data, report, or detailed disclosures. It is not a report, financial statement, or regulatory filing with substantive content but rather a brief announcement to update records. Given the short length (973 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS), which serves as a general category for miscellaneous announcements that do not fit other specific categories.
2024-01-31 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 31st December, 2023' and is issued pursuant to SEBI regulations related to the monitoring of proceeds from a Rights Issue. It contains detailed information about the utilization of funds raised through the Rights Issue, including certifications, bank statements, and comments from the monitoring agency and the board of directors. The report is a regulatory compliance document monitoring the use of capital raised, not a financial performance report or earnings release. It is not an announcement of a report but the report itself, with substantive content and analysis. This fits the category of a Capital/Financing Update (CAP), as it relates to monitoring the use of capital raised through a financing activity (Rights Issue).
2024-01-30 English
Investor Presentation
Interim / Quarterly Report Classification · 100% confidence The document is a press release and investor presentation announcing the unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31st December 2023. It contains detailed financial highlights, business updates, and a conference call announcement for discussing these results. The content includes actual financial data such as revenue, EBITDA, profit/loss figures, and segment performance, which are typical of an Interim / Quarterly Report. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year confirms this classification. It is not merely an announcement of a report or a certification, but a substantive financial report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-01-30 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31st December 2023. It includes detailed financial highlights, business updates, and a conference call invitation for discussing these results. The content contains actual financial data and analysis for Q3 and 9M FY2024, including revenue, EBITDA, profit/loss, and segment performance. The presence of detailed financial statements and management commentary indicates this is a comprehensive interim/quarterly report rather than just a brief earnings release or announcement. The document also includes an investor presentation, which is typical for quarterly financial reporting. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-01-30 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement dated January 30, 2024, from Piramal Pharma Limited regarding the approval of unaudited financial results for the quarter and nine months ended December 31, 2023. It includes standalone and consolidated financial results, notes on accounting principles, details on rights issue proceeds utilization, and an independent auditor's limited review report. The document contains substantive financial data and analysis, including income, expenses, profit before tax, tax expenses, and earnings per share. The presence of a limited review report by statutory auditors confirms it is an interim financial report. The document is not merely an announcement of a report or a certification letter but contains the actual financial results and related disclosures for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-01-30 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Piramal Pharma Limited dated January 30, 2024, reporting the approval of unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023. It includes comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, earnings per share, and notes explaining accounting policies and significant events. The document also contains an Independent Auditor's Review Report on the interim financial results, confirming the review of the unaudited financials in accordance with Indian Accounting Standards for interim reporting (Ind AS 34). The presence of detailed financial statements and auditor's review for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is not merely an announcement or a certification but contains substantive financial data and analysis for the interim period. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2024
2024-01-30 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.